Bloomberg (September 13)
“President Donald Trump’s most concrete step to rein in unprecedented US budget deficits — sweeping tariff hikes — faces the danger of a legal reversal that would put the nation’s finances on an even shakier footing.” While expert opinion is somewhat divided on the rationale for tariffs, “few disagree that tariff hikes are indeed generating a new stream of cash for the Treasury,” a stream that could disappear with the impending Supreme Court decision, placing “Trump’s deficit plan at risk.”
Tags: Budget deficits, Danger, Decision, Expert, Finances, Legal reversal, Opinion, Rationale, Risk, Shakier, Supreme Court, Tariff hikes, Treasury, Trump, U.S., Unprecedented
Reuters (November 24)
“The German government is working hard to demonstrate the foolishness of the country’s iron-clad ban on large budget deficits.” Though it is suspending the “debt brake” for 2023, “the welcome relief is only temporary, and the harm is done. The budget crisis will cripple the economy for years to come.”
Tags: 2023, Ban, Budget deficits, Cripple, Crisis, Debt brake, Economy, Foolishness, German, Government, Harm, Iron-clad, Relief, Suspending, Temporary
Washington Post (December 2)
Pfizer’s planned tax inversion highlights a dilemma “of almost-impenetrable complexity and contentiousness: How to tax multinational companies?” To minimize their taxes, “large global firms…are becoming more aggressive.” At the same time, governments are “increasingly desperate to raise tax revenue to pay for aging societies and cover persistent budget deficits.”
Tags: Aging societies, Budget deficits, Dilemma, Governments, Inversion, Multinationals, Pfizer, Taxes
